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a  b  s  t  r  a  c  t
Cancer  conveys  profound  social  and  economic  consequences  throughout  the  world.  Metastasis  is  respon-
sible for  approximately  90%  of  cancer-associated  mortality  and,  when  it occurs,  cancer  becomes  almost
incurable.  During  metastatic  dissemination,  cancer  cells  pass  through  a series  of complex  steps  including
the establishment  of  tumour-associated  angiogenesis.  The  human  endothelial  progenitor  cells  (hEPCs)
are a cell  population  derived  from  the  bone  marrow  which  are  required  for  endothelial  tubulogenesis
and  neovascularization.  They  also  express  abundant  inﬂammatory  cytokines  and  paracrine  angiogenic
factors.  Clinically  hEPCs  are  highly  correlated  with  relapse,  disease  progression,  metastasis  and  treatment
response  in malignancies  such  as  breast  cancer,  ovarian  cancer  and non-small-cell  lung carcinoma.  It has
become evident  that  the hEPCs  are  involved  in  the  angiogenesis-required  progression  and  metastasis  of
tumours.  However,  it is  not  clear  in  what  way  the  signalling  pathways,  controlling  the  normal  cellular
function  of human  BM-derived  EPCs,  are  hijacked  by  aggressive  tumour  cells  to  facilitate  tumour  metas-
tasis.  In addition,  the  actual  roles  of  hEPCs  in  tumour  angiogenesis-mediated  metastasis  are  not  well
characterised.  In this  paper  we  reviewed  the  clinical  relevance  of  the  hEPCs  with  cancer  diagnosis,  pro-
gression  and  prognosis.  We further  summarised  the  effects  of  tumour  microenvironment  on  the  hEPCs
and  underlying  mechanisms.  We  also  hypothesized  the  roles  of  altered  hEPCs  in tumour  angiogenesis
and  metastasis.  We  hope  this  review  may  enhance  our understanding  of  the  interaction  between  hEPCs
and  tumour  cells  thus  aiding  the development  of cellular-targeted  anti-tumour  therapies.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC∗ Corresponding author.
E-mail address: cuiy7@cf.ac.uk (Y.-X. Cui).
ttp://dx.doi.org/10.1016/j.critrevonc.2016.02.010
040-8428/© 2016 The Authors. Published by Elsevier Ireland Ltd. T
http://creativecommons.org/licenses/by-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. IntroductionThe endothelial progenitor cells (EPCs) are a subtype of stem
cells that reside within a stem cell niche in the bone mar-
row and are required in some repairing processes, such as
his is an open access article under the CC BY-NC-ND license
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yocardial ischemia and infarction, limb ischemia and wound
ealing. In particular they are deﬁned by co-expression of the mark-
rs of CD34, CD309 (VEGFR-2/KDR) and CD133. Notably, CD133 is
xpressed in the most primitive EPCs and lost during maturation
o endothelial cells, in which other markers are expressed, such
s vascular endothelial cadherin and von Willebrand factor. The
requency of CD34+ cells which also express CD309 and CD133 in
eripheral blood in healthy individuals is around 0.4 ± 0.2% of the
otal CD34+ population (0.002% of total mononuclear cells). Cord
lood and foetal liver-derived CD34+ cells contain 1.4 ± 0.5% and
.2 ± 0.3% CD133+/CD309+ cells, respectively (Hristov and Weber,
004; Peichev et al., 2000). In normal physiological conditions EPCs
re quiescent but in response to a vascular injury, they acquire the
bility to circulate in the peripheral blood, proliferate and differ-
ntiate into mature endothelial cells. In response to a gradient of
rowth factors and cytokines released by the damaged site, EPCs
re able to migrate and home to the local endothelium, contribut-
ng to neovasculature (Peichev et al., 2000; Asahara and Kawamoto,
004). There are no systematic studies on the physiological varia-
ion of EPCs but it has been proved that their number may  varies
n pathological conditions. For example, the level of circulating
PCs is lower in diabetic and vascular disease patients than in
ealthy people (Fadini et al., 2006; Vasa et al., 2001) and rises after
n acute myocardial infarction and in some malignancies (Nowak
t al., 2010a; Massa et al., 2005). EPCs are activated not only by
 vascular injury, but also in the sites where the oxygen level is
ow such as foetal liver, umbilical cord blood and tumour tissues
Asahara and Kawamoto, 2004). EPC isolation and enumeration
s made difﬁcult by the low number of cells in peripheral blood,
ethodological issues and a lack of consensus on phenotypic iden-
iﬁcation. Despite this, EPCs can be isolated from peripheral blood
hrough three general approaches and using speciﬁc methodolo-
ies to enrich their number. In the ﬁrst approach EPCs are isolated
y cultivation of mononuclear peripheral blood cells (PBMCs) in
bronectin-coated plates. After 2–3 weeks, the adherent cells that
re able to ingest acetylated low density lipoprotein (acLDL) and
o bind speciﬁc lectins are classiﬁed as EPCs. Circulating EPCs may
e also puriﬁed using monoclonal antibodies and ﬂuorescence acti-
ated cell sorting (FACS). Finally, EPCs may  be obtained using two
ifferent in vitro colony forming assays, the colony forming unit-
ill (CFU-Hill) and endothelial colony forming cells (ECFC) assays
Yoder and Ingram, 1796). In this review, we summarised the clin-
cal relevance of EPCs in cancer. In particular, we evaluated the
ossible biomarker value of EPCs in cancer, and explored how
umour microenvironment may  regulate the activation, mobilisa-
ion and homing of EPCs. We  also highlighted the internal and
xternal stresses which contribute to the interaction of tumour cells
nd EPCs. We  further proposed possible therapeutic strategies by
argeting tumour-associated EPCs to halt tumour angiogenesis and
etastasis.
. Signiﬁcance of EPCs in angiogenic-mediated tumour
etastasis
Although the mechanisms that regulate the migration of cancer
ells from the primary to secondary organs have been widely stud-
ed, some aspects of this multistep process are still unclear (Hoshino
t al., 2015). Stem cells are recruited to the tumour site to enhance
ew blood vessel formation by secreting angiogenic molecules
nd/or by trans-differentiation into endothelial-like cells, such
s dendritic cell precursors, circulating mesenchymal stem cells
MSCs) and a subset of adult peripheral blood leukocytes functions
s endothelial cell progenitors (Coukos et al., 2005; Harraz et al.,
001; Xu and Li, 2014). Haematopoietic precursor cells from the
one marrow, including EPCs, appear to be activated on speciﬁcgy/Hematology 100 (2016) 177–189
sites before the tumour cells get there, contributing to the forma-
tion of a “pre-metastatic niche”, in which non-cancer cells promote
metastasis development. Changes in the level of circulating EPCs in
patients with cancers can indicate treatment response as well as
the grade of the malignancy. Thus, the number or functional alter-
ation of EPCs in peripheral blood of cancer patients may be used as
a biomarker to evaluate the risk of metastasis and raises the possi-
bility that targeting circulating progenitors may  have a therapeutic
value.
2.1. Clinical relevance of EPCs in cancer
The condition in which a region of the body is deprived of an
adequate oxygen supply is called “hypoxia”. During embryonic
development, where the level of oxygen is low, EPCs contribute
to the physiological vasculogenesis of the embryo (Schmidt et al.,
2007). In adults, EPCs can be activated by a vascular injury or
hypoxia and play an important role in neo-vasculogenesis, the for-
mation of new vessels during post-natal life (Ceradini et al., 2004).
In normal conditions, EPCs are mobilized from the bone marrow
in response to paracrine factors released by the injured tissues,
such as Vascular Endothelial Growth Factor (VEGF) and Stromal
cell-Derived Factor 1 (SDF-1). When the wound is repaired, the
physiological state is established again and EPCs are not recruited
anymore. In pathologic states such as tumour aggression, when a
chronic state of hypoxia and/or inﬂammation occurs, the EPCs are
constitutively activated and play a double role: from one side, they
contribute to the tumour sprouting thanks to their ability to form
new vessels. On the other side by releasing paracrine secretions of
pro-angiogenic growth factors, they contribute to maintaining an
inﬂammatory state, one of the essential biological characteristics
for tumour growth and progression (Hanahan and Weinberg, 2011).
It has been shown that hypoxia itself is good for growth and survival
of stem and progenitor cells, inducing a “protective” autophagy and
moderate apoptosis during times of cellular stress. However, if the
exposure to low oxygenation in tissues becomes a chronic state,
the result is a major apoptosis and destructive necrosis (Sharma
and Wu,  2013).
It  has been demonstrated that EPCs are mobilized from the
bone marrow in different types of malignancies, such as hepato-
cellular carcinoma, lung, pancreatic and breast cancer (Yu et al.,
2007; Nowak et al., 2010b; Starzynska et al., 2013; Ono et al.,
2014; Buchanan et al., 2012). Several studies have shown that in
different types of cancers, the EPC level is very high in both tis-
sues and peripheral blood of cancer patients compared to those
of healthy donors. For instance, the increase of EPCs in periph-
eral blood of hepatocellular carcinoma patients was  observed (Yu
et al., 2007). In patients with Non-Small-Cell Lung Carcinoma
(NSCLC) and Small Lung Carcinoma (SLC) the number of circulating
EPCs increases in proportion to the disease progression, and there
appears a correlation between circulating EPC concentration and
the stage of the malignancy (Nowak et al., 2010b). If further stud-
ies can conﬁrm this ﬁnding, it may  be possible to consider the EPCs
from peripheral blood as non-invasive biomarkers for the monitor-
ing of tumour progression, in concert with other tumour-speciﬁc
biomarkers already available. Studies also suggested a possible
application of circulating EPCs as predictors of the malignancy
grade of some tumours. In fact, a decrease of circulating EPCs has
been observed in patients who  respond well to anticancer treat-
ments. Circulating EPCs have also been proposed to be prognostic
and predictive biomarkers for gastric cancer patients treated with
chemotherapy (Ahn et al., 2010). Indeed there is a reduction of
EPC levels in breast cancer patients after cytotoxic therapy (Kuo
et al., 2012). The level of EPCs in blood can be distinguished from
healthy donors, NSLC patients who  responded well to the treat-
ment (chemotherapy/radiotherapy) and NSLC patients who did not
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espond to treatment (Dome et al., 2006). The same group also
howed that there was a higher incidence of death in patients who
ad higher EPC levels in blood before the treatment, compared with
hose with lower level of EPCs. This observation strengthens the
ypothesis that EPC levels in NSCLC may  correlate with tumour
urden (Dome et al., 2006). However, the clinical relevance of EPCs
an be complicated depending on particular treatments in lung can-
er. For instance, some chemotherapeutic agents may  induce EPC
obilisation from the bone marrow to the tumour site, supporting
he tumour spread. And although a combination of anti-angiogenic
rugs may  amplify the effect of some anti-cancer therapies, in a few
ases the opposite effect has been reported (Shaked et al., 2008).
.2. EPCs in cancer diagnosis and prognosis
EPCs are required for the regulation and protection of endothe-
ia, as well as the formation of new vessels. Consequently, their
umber increases in response to chemokines released in the
icroenvironment after a trauma or when a condition of chronic
nﬂammation occurs. Numerous studies have focused on EPCs in
eripheral blood to evaluate whether a variation in their num-
er could represent a tool to predict a pathological state. It is well
nown that in patients affected by different diseases the number
f circulating EPCs may  vary within patients affected by the same
athology and between patients and healthy people. Moreover,
n some cases a correlation of circulating EPCs with clinical out-
omes has been proposed. For example, low levels of EPCs have
een observed in diabetic and vascular disease patients. Diabetes
s characterised by hyperglycaemia and impaired endothelial func-
ion. High glucose levels result in a reduction of endothelial nitric
xide synthase (eNOS) activity and nitric oxide (NO) availability
hich is important both for the mobilisation and function of EPCs.
herefore there is a reduction of circulating EPCs when glucose in
lood is too high. It has also been observed that EPCs proliferate at a
ery low rate in diabetes patients and their number is signiﬁcantly
educed (Tepper et al., 2002; Fadini et al., 2007; Hamed et al., 2009).
ow level of circulating EPCs seem also to correlate with complica-
ions associated with diabetes, such as peripheral arterial disease
Fadini et al., 2006).
A decrease in EPC numbers is also associated with the pathogen-
sis of vascular complications. EPC number and migratory capacity
re impaired in patients with coronary artery disease (Vasa et al.,
001). It has been shown that reduced levels of circulating EPCs
ay  predict future cardiovascular events, suggesting a possible role
f these types of cells as biomarkers (Schmidt-Lucke et al., 2005).
n the other hand, an increase in EPC numbers in the peripheral
lood of patients with acute lung injury is associated with improved
urvival (Burnham et al., 2005).
As reported previously, in tumours EPCs are mobilized from the
one marrow to contribute to the formation of new vessels and,
ainly for this reason, the levels of EPCs in the blood of cancer
atients is higher than in healthy people (Arbab et al., 2006). It has
een shown that EPCs in peripheral blood may  represent a use-
ul diagnostic and prognostic tool to monitor the clinical state of
atients. In NSCLC a higher level of EPCs correlates with a poor
verall survival. NSCLC patients who achieve a partial or complete
emission after anti-cancer therapy show lower level of circulating
PCs than patients with stable or progressive disease, suggesting
hat the number of EPCs correlates with the treatment efﬁcacy in
his malignancy (Dome et al., 2006). Furthermore it has been shown
hat patients with more advanced stages of both NSCLC and SCLC
ave higher levels of circulating EPCs than patients at a lower stage
robably due to the larger tumour size and the presence of distant
etastases (Nowak et al., 2010b). One study has shown that, in
esponse to some chemotherapy regimens, the number of EPCs in
he plasma of cancer patients continues to increase independentlygy/Hematology 100 (2016) 177–189 179
from the level of cytokines (Roodhart et al., 2010). So far some
hypotheses have been proposed for the use of EPCs as biomarkers to
monitor the progression of the disease and to discriminate between
a good and bad response to therapies. It has been demonstrated that
EPCs may  represent a good marker to evaluate the response of col-
orectal cancer patients to antiangiogenic drugs (Matsusaka et al.,
2011; Ronzoni et al., 2010). Although preclinical studies have been
shown their usefulness for the treatment of some malignancies,
the role of antiangiogenic drugs is controversial especially because
their effects are limited by drug resistance (Shaked et al., 2008).
In breast cancer patients with a relatively high amount of EPCs,
chemotherapy reduces the number of circulating endothelial cells,
which are probably detached from the pre-existing vessels. How-
ever, at the same time, it induces the mobilisation of the EPCs from
the bone marrow. This evidence strengthens the hypothesis that
EPCs may  contribute to tumour-associated angiogenesis and, con-
sequently, the beneﬁcial effects of an early antiangiogenic therapy
in combination with chemotherapy (Fürstenberger et al., 2006).
As shown in Table 1, elevated EPC number can be frequently
observed in some cancers and their relevance for the evaluation of
the stage of a tumour has been proposed. For instance, the number
of EPCs in both cancer-adjacent and cancer tissues of patients with
late-stage gastric cancer was  lower than in early-stage patients.
Thus the EPC number may  represent a diagnostic index although
the role of EPCs in this malignancy has not been well characterised
(Ha and Kim, 2014).
The preliminary data on the possible use of circulating EPCs as a
non-invasive biomarker is promising. They may  be used in concert
with other molecules instead of some invasive prognostic mark-
ers available, such as microvessel density (MVD). For instance, in
some malignancies not only EPC but also VEGF and haematopoi-
etic progenitor cells (HPCs) levels were found higher in patients
than in controls and all of them may  be considered to monitor the
progression of the disease (Nowak et al., 2010a; Jain et al., 2012).
Nevertheless EPC number may  be affected by other conditions, such
as cardiovascular diseases (Bahlmann et al., 2004; Friedrich et al.,
2009). For this reason further studies are necessary to validate the
use of EPCs as biomarker in cancer.
3. Interaction of EPCs and tumour cells in aggressive
tumour microenvironment
The tumour microenvironment has been recognised as the prod-
uct of a developing crosstalk between different cell types. The
direct and indirect interactions between cancer cells, EPCs, inﬂam-
matory immune cells and endothelium support the growth and
spread of tumours. In the following paragraphs the consequences
and mechanisms underlying the alterations of tumours and EPCs in
aggressive tumour microenvironment are described.
3.1. Effect of tumour microenvironment on EPCs
As reported previously, in the cases of ischemia and tumour,
EPCs are mobilised from the bone marrow and hypoxia plays an
important role in their homing. Pathologic hypoxia is the condi-
tion that induces the formation of new capillaries from pre-existing
vessels enabling the oxygen supply to the tumour mass, one of
the crucial characteristics for cancer cell survival (Hanahan and
Weinberg, 2011). The oxygen tension regulates the transcription
activator hypoxia inducible factor (HIF), a dimer formed by two
subunits (HIF1- and HIF1-).  In normoxic conditions HIF1-
is degraded in the proteasome. Conversely, in hypoxia the two
subunits are able to combine together and translocate into the
nucleus, where they activate the transcription of a large num-
ber of genes required for tumour progression, such as vascular
180 V. Flamini et al. / Critical Reviews in Oncology/Hematology 100 (2016) 177–189
Table 1
Increase of circulating endothelial progenitor cells (cEPCs) in some cancers.
Cancer Treatment cEPCs Correlation with the stage Reference
Liver None Higher in patients than in
healthy people
– (Yu et al., 2007)
Lung  (NSCLC and SCLC) Various chemotherapeutic
regimens
Higher in patients than in
healthy people
Yes (Nowak et al., 2010a)
Lung
(NSCLC)
Gemcitabine and cisplatin
(plus radiotherapy in some
cases)
Higher in patients than in
healthy people
Yes (Dome et al., 2006)
Breast  colorectal, ovarian,
esophagus, prostate, head and
Various chemotherapeutic
regimens
Higher after the ﬁrst cycle of
chemotherapy
–  (Roodhart et al., 2010)
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2neck, sarcoma, cervix
Breast  Anthracycline and/or taxane
based chemotherapy
Higher after c
patients with
ndothelial growth factor-A (VEGF-A), platelet-derived growth fac-
or (PDGF), erythropoietin, stromal cell-derived factor (SDF1-)
nd C-X-C chemokine receptor type 4 (CXCR 4) (Paliege et al., 2010;
ang et al., 2016; Schioppa et al., 2003). The loss of function of
IF as a dimer inhibits EPC proliferation and differentiation, thus
educes their ability to form new vessels (Branco-Price et al., 2012;
iang et al., 2006). The knock-down of HIF1-  in EPCs has beneﬁcial
ffects, not only on pathologic angiogenesis but also on the remod-
lling of blood vessel which return to their regular shapes (Du et al.,
008).
Another common feature of neoplastic diseases is the ability of
ancer cells to avoid the immune response and maintain a chronic
tate of inﬂammation (Hanahan and Weinberg, 2011). During the
nﬂammation process, cytokines are released from the damaged
r hypoxic tissue, producing a molecular gradient which guides
PCs, pericyte progenitors and CD45+ vascular modulatory cells
rom the bone marrow to the inﬂamed tissue (Ahn and Brown,
009). The up-regulation of cytokines and some interleukins pro-
uced by the cancer tissue itself and by macrophages is a common
ondition in cancer, where the inﬂammation persists (Mosser and
dwards, 2008). However, cytokines have a crucial role not only in
he maintenance of a malignant microenvironment but also in sur-
ival, growth, mutation, proliferation and differentiation of both
umour and stromal cells (Balkwill and Mantovani, 2001).
One of the most widely studied cytokines using in vitro and
n vivo models is VEGF, which is overexpressed in different types
f malignancies. VEGF acts through three tyrosine kinase receptors
VEGFR1, 2 and 3), two of which are speciﬁcally involved in angio-
enesis (VEGFR1 and VEGFR2) (Ferrara et al., 2003; Senger et al.,
994; Gerber et al., 1998). VEGF has various effects on endothelial
ells, including the increase of vascular permeability, facilitation of
urvival via reducing cell apoptosis and the support of tumour tis-
ue adhesion by reshaping the extracellular matrix of the malignant
ells (Senger et al., 1994; Pidgeon et al., 2001). It has been demon-
trated that in tumours, a high plasma level of VEGF promotes
obilisation of EPCs from the bone marrow (Lyden et al., 2001a).
oreover, VEGFR1-deﬁcient mice show several vascular malfor-
ations, suggesting the importance of this cytokine in vascular
emodelling. Therefore, the effect of VEGF on EPCs is to stimulate
heir mobilisation from the bone marrow and their proliferation.
EGF can improve the proliferation of EPCs by increasing the level of
O following the activation of the phosphatidyl-inositol-3-kinase
PI3K)-Akt/eNOS signalling pathway (Chen et al., 2011a). NO is an
biquitous intercellular messenger, and in blood vessels its syn-
hesis is controlled by the endothelial enzyme eNOS (Knowles and
oncada, 1992). In physiological conditions, NO contributes to the
aintenance of vascular tone and blood pressure (Calver et al.,
992). When the level of oxygen becomes lower, the increase of
NOS by stem cells from the bone marrow promotes migration and
roliferation of these cells and tubule formation (Branco-Price et al.,
012; Lu et al., 2014). NO stimulates matrix metalloproteinase 9therapy in
PCs
– (Fürstenberger et al., 2006)
(MMP-9) that activates the detachment between EPCs and the bone
marrow niche through the cleavage of the membrane Kit ligand
(mKitL). mKitL is converted to the soluble form (sKitL) and binds
the EPC membrane, leading to their release into the bloodstream.
VEGF also regulates angiogenesis together with two  paracrine
factors, angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2). Ang-1
is expressed in many adult tissues and Ang-2 is primarily pro-
duced by endothelial cells at the site of active vascular remodelling
(Huang et al., 2010). Both bind the tyrosine kinase receptor Tie-
2 in an antagonistic manner. Ang-1 promotes vessel maturation,
integrity and vascular quiescence. Ang-2 causes the dissociation
of pericytes from the tumour vasculature, promoting instability of
blood vessels (Maisonpierre et al., 1997; Fagiani and Christofori,
2013). During the ﬁrst stages of neoplastic transformation, VEGF
and Ang-1 promote the mobilisation of EPCs via remodelling the
BM vascular architecture (Hattori et al., 2001). When VEGF levels
are high, VEGF stimulates the release of Ang-2 by endothelial cells
in the interior tumour vessels, reducing the signal for vessel regres-
sion by Ang-1 competing for the binding to Tie-2 receptor. It has
been shown that VEGF and Ang-2 act in a synergistic way  to pro-
mote angiogenesis. In fact, the depletion of both VEGF and Ang-2
activity results in a signiﬁcant inhibition of tumour growth and EPC
recruitment (Kienast et al., 2013; Visconti et al., 2002).
As mentioned, a chronic state of hypoxia produces major
apoptosis and necrosis, contributing to the maintenance of an
inﬂammatory environment (Shaked et al., 2008). Some pro-
inﬂammatory cytokines, such as interleukins and tumour necrosis
factor (TNF-) are involved in tumour growth and progression, and
have effects on EPCs (Voronov et al., 2014). In particular, TNF-
is able to reduce EPC proliferation, migration and tubule forma-
tion capacity in a dose- and time-dependent manner (Chen et al.,
2011b).
3.2. Mechanisms by which tumour cells modulate the behaviour
of EPCs
EPCs participate in tumour progression due to their ability to
form new vessels and secrete paracrine factors (Gao et al., 2008a).
Both their physiological and acquired pathological characteristics
result from signals coming directly from the tumour cells and indi-
rectly from cells modiﬁed by the tumour and/or microenvironment.
Hypoxia alters the gene expression of different types of cells,
changing their morphology and properties. For instance the
tumour-associated macrophages (TAMs) play a crucial role in can-
cer (Lewis et al., 1999) and their high density is correlated with a
poor patient prognosis (Bingle et al., 2002). TAMs and other cancer-
activated cells are able to inﬂuence EPC behaviour by secreting
growth factors and cytokines, such as Transforming Growth Fac-
tor  (TGF-),  Tumour Necrosis Factor  (TNF-)  and interleukins
(Locksley et al., 2001; Lewis and Pollard, 2006).
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TGF- is a family of cytokines that regulate many aspects
f cellular behaviour, such as proliferation, differentiation and
poptosis. TGF- members regulate cell responses by binding
he serine/threonine kinase Smad receptors or through differ-
nt Smad-independent pathways (Derynck and Zhang, 2003). The
nteraction between TGF- ligands and their receptors activates
he downstream effectors, which transmit the signals from the cell
embrane to the nucleus and result in subsequent transcription of
arget genes (ten Dijke et al., 2000). In physiological conditions TGF-
 acts as a tumour suppressor, but during neoplastic transformation
t promotes cell growth, motility and invasion. TGF-1 is the mem-
er of TGF- family which is speciﬁcally involved in angiogenesis.
onsiderable studies have shown that TGF-1 is able to inﬂuence
PC behaviour (Imamura et al., 2010; Sales et al., 2006; Evrard et al.,
012). Endothelial cells express two TGF- receptors, ALK1 and
LK5, which act in an antagonistic way (Goumans et al., 2002). The
GF-/ALK1 signalling activates the transcription of the Inhibitor
f DNA Binding (ID) protein molecules. In particular, ID-1 is highly
xpressed in EPCs and promotes the proliferation and migration
f EPCs through P13K/Akt/NFB/survivin signalling cascades (Gao
t al., 2008a; Li et al., 2012). Conversely, when TGF- binds ALK5
eceptor, it stimulates the transcription of the plasminogen acti-
ator inhibitor 1 (PAI-1), which prevents vascular cell migration
nd angiogenesis (Siegel and Massague, 2003). The different use of
he two receptors by TGF- may  explain the double roles of this
ytokine in endothelial cells and EPCs. The high expression of ID-
 in EPCs suggests that the preferential use of ALK5 receptor by
GF- may  be one of the strategies adopted by the tumour for its
xpansion.
In normal conditions the EPCs are quiescent and reside in their
M niche in close association with haematopoietic stem cells and
tromal cells. Notch is one of the key components of the BM niche.
t is a transmembrane protein that is involved in many aspects
f differentiation and cell fate determination. Perturbation of the
otch pathway is linked to a spectrum of diseases including can-
er (Louvi and Artavanis-Tsakonas, 2006; Rampias et al., 2014;
heng et al., 2014a; Espinoza and Miele, 2013). In Mammals, the
anonic Notch signalling involves four Notch receptors (Notch1-
) and six Notch ligands (Jagged1-2, Delta1, 3, 4 and X-Delta2)
D’Souza et al., 2008). When a Notch receptor interacts with its
djacent ligand or on the surface of an opposing cell, the recep-
or undergoes two proteolytic cleavages and the activated form of
otch (NICD-Notch Intracellular Domain) is released into the cell.
ICD translocates into the nucleus, leading to transcriptional acti-
ation of target genes. Notch is required for the maintenance of the
uiescence of the stem cells in the bone marrow, including EPCs.
ne of the activators of Notch signalling is Tumour Necrosis Fac-
or (TNF), secreted mainly by the macrophages. A tumour state can
nduce the modiﬁcation of macrophages that secrete TNF and other
ytokines, promoting the overexpression of Notch receptors on the
ell surface of osteoblasts (Varnum-Finney et al., 2003; Fernandez
t al., 2008; Kwon et al., 2009). The interaction between Notch lig-
nds on the osteoblasts and Notch receptors of the EPCs permits
he activation of EPCs. Notch signalling activation in progenitors is
ainly a result of Jagged1 activity. In fact, it has been demonstrated
hat the loss of Jagged1 expression leads to a reduced endothelial
ineage gene expression in BM progenitors, lower EPC colony for-
ation, reduced migration and loss of the ability of EPCs to form
ew vessels (Kwon et al., 2008).
TNF- is a master regulator of inﬂammation and is produced by
umour and inﬂammatory cells. In tumours it can promote tumour
rogression by supporting angiogenesis or induce the apoptosis of
ancer cells. TNF- has been shown to act as both a positive and
egative regulator of haematopoietic progenitor cells (Cuturi et al.,
987; Caux et al., 1993). The divergent effects of TNF- depend on
ts concentration, duration of exposure (Fajardo et al., 1992) andgy/Hematology 100 (2016) 177–189 181
type of targeted cells (Balkwill, 2009). Actually at low concentra-
tion TNF- promotes angiogenesis by upregulating the levels of
VEGF, bFGF and IL-8. In contrast, when its concentration becomes
higher, it prevents the formation of new vessels (Fajardo et al.,
1992; Caporali et al., 2008). The different roles of TNF- can be
attributed to its ability to bind two  distinct receptors: p55/TNFR1
and p75/TNFR2. TNF-/p55 signalling increases the expression of
some genes that inhibit the apoptotic effect of TNF- acting via the
NF-B pathway. On the other hand, TNF-/p75 mediates apopto-
sis and cell cycle arrest. The role of TNF- in EPCs is to promote
their survival, migration and incorporation into nascent vessels by
binding the p75 receptor (Jacobsen et al., 1994). An in vivo study
clearly demonstrated that TNF-/p75 signalling induces the apo-
ptosis of EPCs in p75KO mice (Sasi et al., 2011). It can be concluded
that the main effect of TNF- on EPCs during neoplastic transfor-
mation is to reduce their number by inducing apoptosis. Moreover,
TNF- enhances the expression of VCAM, ICAM, P-selectin and E-
selectin, adhesion molecules in endothelial cells which supports
the EPC adhesion in the hypoxic sites (Gong et al., 2011).
Some studies have shown the role of interleukins (ILs) in
survival, proliferation and differentiation of hematopoietic progen-
itor/stem cells. For instance, IL-1 is a potent immunoregulatory
and proinﬂammatory cytokine secreted by the activated immune
cells. IL-1 increases the number of EPCs, their viability, prolif-
eration and capacity to form new vessels in vitro acting through
ERK-MAPK signalling (Rosell et al., 2009). Another study shows
that IL-1 upregulates VEGF-A production in vitro through the
phosphatidyl-inositol-3kinase-Akt signalling pathway (Yang et al.,
2012), enhancing the effects of EPCs in tumour spread. Moreover,
in malignancies, cross-talk between EPCs and activated monocytes
occurs: after EPC activation and mobilisation, EPCs themselves are
able to increase IL-1 production in monocytes, contributing to
the maintenance of a pro-inﬂammatory environment (Zhang et al.,
2013). During neoplastic transformation, normal endothelial cells
(NECs) are modiﬁed into tumour-derived endothelial cells (TECs)
and play a key role in EPC differentiation, thanks to their acquired
capability to release the cytokine IL-3 into the tumour microen-
vironment. IL-3 induces the expression of adhesion molecules
in TECs, such as mKitL, through the Akt pathway. In angiogenic
sites, mKitL acts as an adhesion receptor for EPCs, interacting
with c-Kit receptors of EPCs (Dentelli et al., 2011). So, IL-3 pro-
motes both the recruitment and adhesion of EPCs in inﬂammation
sites. Furthermore, a microenvironment containing IL-3 stimulates
BM-derived angiogenic cell proliferation and speciﬁcation via a
STAT5-mediated pathway (Zeoli et al., 2008). Finally, it has been
shown that IL-6 plays a role as a pro-angiogenic cytokine. EPCs pos-
sess IL-6 receptors and a previous study demonstrates that IL-6 is
able to bind its receptor on EPCs and contributes to angiogenesis
through the activation of both REK-1/2 and STAT3 pathways (Fan
et al., 2008).
3.3. Effects of EPCs on cancer invasion in tumour
microenvironment
Endothelial cells and the cells of the immune system promote
the directional movement and adhesion of EPCs to neovessels due
to their ability to secrete paracrine factors, for which EPCs have
receptors. In cancer, the cross talk between EPCs, inﬂammatory
cells and the endothelium supports the formation of the ideal
microenvironment for tumour spread. Although the mechanisms
that regulate EPC mobilisation have been well described (Cui and
Madeddu, 2011), the contribution of EPCs to the metastatic process
has not been completely characterised. In tumours the chronic state
of hypoxia makes the cells constitutively active. HIF1- induces the
release of stromal cell-derived factor 1 (SDF-1) chemokine from the
tumour cells, endothelium, stromal ﬁbroblasts and platelet gran-
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les (Ceradini et al., 2004; Mohle et al., 1998; Orimo et al., 2005;
in et al., 2006). The receptor of SDF-1 is CXCR4, which is widely
xpressed in the differentiated EPCs. In the ﬁrst stages of neoplastic
ransformation the gradient of SDF-1, together with the high con-
entration of eNOS, attracts progenitor cells toward the hypoxic
issue. This may  represent one of the strategies adopted by the
ancer to maintain a good pool of cells for the generation of new
essels. During the tumour progression, EPCs start to secrete SDF-1
nd VEGF-1 spontaneously (Urbich et al., 2005). Tumour cells and
ature endothelial cells express CXCR4 on their cell surface, so the
radient of SDF-1 produced by the EPCs may  promote the extrava-
ation and development of a pre-metastatic site before the arrival
f the malignant metastatic cells (Kaplan et al., 2005; Jin et al.,
012). In addition, the indirect interaction between the resident
broblasts and BM-derived progenitor cells participates in the for-
ation of the pre-metastatic niche (Kaplan et al., 2005). In fact,
he BM-derived progenitor cells, including EPCs, express integrin
41 and VEGFR1. The growth factors released into the microen-
ironment up-regulate ﬁbronectin in ﬁbroblasts, which is one of the
igands of 41, contributing to their directional migration. Based
n this experimental evidence, it has been demonstrated that the
se of antibodies against CXCR4 improves the anti-tumour effect
f chemotherapy, and the knock-out of VEGFR1 in EPCs reduces
umour metastasis development (Hassan et al., 2009). SDF-1 reg-
lates the trafﬁcking of progenitor cells from and to the bone
arrow. If the cells of the immune system produce SDF-1, EPCs
ay  be attracted to distant sites and start to produce SDF-1 spon-
aneously, promoting the spread of the tumour in distant sites. The
xistence of a pre-metastatic site is consistent with the seed and
oil theory postulated by Paget in 1889 and one of the hypotheses
s that EPCs may  play a crucial role in its formation.
ig. 1. Endothelial progenitor cells (EPCs) activation in tumour microenvironment. Th
onstitutive transcription of paracrine factors which stimulate the activation and relea
I3K/AKT cascade activates the nitric oxide synthase enzyme (NOS) increasing the level o
PCs,  into circulation. In the bloodstream EPCs home to the hypoxic sites with response to
aracrine factors in return, which increase the vessel permeability thus promote the me
gure  legend, the reader is referred to the web  version of this article.)gy/Hematology 100 (2016) 177–189
Some evidence suggests an active role for EPCs in cell migration
and invasion also due to their ability to activate MMP-9 (Shih et al.,
2014), an enzyme responsible for disintegration of the basement
membrane. The subsequent release of Kit-ligand and VEGF-A in the
microenvironment supports the formation of a metastatic niche.
Moreover, ID1 and ID3 inhibition prevents metastatic growth, sug-
gesting a crucial role for these proteins in metastasis (Gao et al.,
2008a; Kaplan et al., 2005). The up-regulation of MMP-9 by SDF-1
normally occurs in the bone marrow for the mobilisation of progen-
itor cells (Petit et al., 2007) and cancer uses the same mechanism to
support its spread. Considering these facts, it is possible that SDF-1
facilitates cell egress not only during the physiological processes
but also in pre-metastatic niche development (Fig. 1).
4. Roles of internal and external stresses in interaction of
tumour cells and EPCs
Cells are affected by many internal and external stimuli, some
of which may  induce stresses resulting in damage to the structure
or function of proteins, DNA or other essential macromolecules.
The capacity of the cells to respond to stress depends on the
proteome expressed at a particular time and is species- and cell
type-dependent (Kültz, 2005). In response to stress a cell can re-
establish cellular homeostasis or adopt an altered state (Milisav,
2011). During the development of human tumours, cells acquire
some characteristics allowing them to survive in different envi-
ronments. In response to external stimuli cancer cells change their
morphology and gene expression by direct alteration of DNA or
modiﬁcations in epigenetic regulation.
The typical stresses involved in neoplastic transformation can be
categorised as oncogenic, genotoxic and non-genotoxic. Oncogenic
stress occurs when there is activation of anti-oncogenic pathways,
e chronic state of hypoxia (blue) in the tumour microenvironment leads to the
se of the EPCs from the bone marrow through the PI3K/AKT signalling pathway.
f nitric oxide (NO) (green) which induces the release of progenitor cells, including
 pro-angiogenic cytokines secreted by tumours. Activated EPCs express and secrete
tastasis of malignant tumours. (For interpretation of the references to color in this
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ue to the inactivation of tumour suppressor genes and/or the
ctivation of oncogenes. Non-oncogenic stress is induced by car-
inogens that can be classiﬁed as genotoxic and non-genotoxic.
enotoxic carcinogens (UV rays, ionizing radiation, drugs, and
hemicals) form complexes with DNA leading to various type
f damage such as removal of bases or formation of cross-links
etween the two helices. On the other hand, the non-genotoxic
arcinogens (hypoxia, temperature, growth factors and viruses)
amage DNA by disrupting cellular structure, changing the rate and
egulation of cellular processes (Lee et al., 2013).
In response to one of the stresses reported above, the ﬁrst
trategy for preventing the proliferation of potential cancer cells
s to arrest cell growth. This process is called “senescence” and
an be induced by different triggers. Primary cells are not able
o proliferate indeﬁnitely, mainly due to the attrition of telom-
rases and reach “replicative senescence” (Hayﬂick, 1998). Certain
ypes of stress triggers, such as DNA damage, oncogenic stress and
lterations in the epigenetic regulation, produce stress-induced
remature senescence (SIPS) (Serrano and Blasco, 2001). Given that
ancer is an age-related disease, it is reasonable to consider cel-
ular senescence as an important mechanism for both preventing
nd promoting tumourigenesis, depending on aging. It was  demon-
trated that in young epithelial tissues the environment suppresses
he expression of potential neoplastic phenotypes. With age, senes-
ent cells of the basement stroma accumulate and secrete factors,
uch as cytokines and growth factors that contribute to tumour pro-
ression (Campisi, 2003). As reported previously, EPCs contribute
o the maintenance of a chronic state of inﬂammation by increase
ecrosis. It has also been demonstrated that a prolonged inﬂamma-
ory stimulation increases senescence in EPCs (Zhang et al., 2009)
nd it is possible that both senescence and necrosis of EPCs con-
ribute to tumour survival. The role of necrosis in cancer has been
stablished; in particular in EPCs it may  contribute to the sup-
ort of the ideal microenvironment for the tumour spread. On the
ther hand, it is possible that a small proportion of EPCs attempt
o protect themselves from tumour progression by activating the
poptotic pathway. However further investigations are needed to
etter understand the precise contribution of these two processes
n both cancer cells and EPCs during malignant progression.
The DNA-damage response (DDR) is a system adopted by cells
o detect DNA lesions, signal their presence and promote repair.
he inability to repair DNA damage can result in cell cycle arrest,
enescence or apoptosis, leading to various disorders including can-
er. In response to DNA damage both ataxia telangiectasia mutated
ATM) kinase and DNA dependent protein kinases are activated to
revent the proliferation of potential malignant cells. Senescence
an be induced especially by alterations in telomere length. The
elomere-binding protein TRF-2 plays a central role in telomere
aintenance and protection against end-to-end fusion of chro-
osomes (Karlseder et al., 1999). It has been shown that the
verexpression of TRF2 leads to a “juvenation” of EPCs by delay-
ng replicative senescence and improving their migration ability.
n this case TRF2 protein might correlate with cellular aging since
lder EPCs assume the same age characteristics of the younger cells,
uch as the ability to migrate to distant sites (Assmus et al., 2003;
pyridopoulos et al., 2004). EPC senescence may  be associated also
ith telomerase activity. As reported above, the PI3 K/AKT sig-
alling pathway plays an important role in EP metabolism through
ncreasing NO levels, which subsequently activates telomerase and
elays EPC senescence. Positive regulators of the PI3 K/AKT sig-
alling pathway, such as statin, VEGF, HDL and oestrogen lead the
pregulation of human telomerase reverse transcriptase (hTERT) at
he transcriptional level and phosphorylated hTERT that can trigger
he telomerase activity post-transcriptionally (Yang et al., 2008).
evertheless, some evidence suggests that high levels of ROS main-
ain Akt in the dephosphorylated state, leading to a decrease ingy/Hematology 100 (2016) 177–189 183
telomerase activity and accelerated EPC senescence (Yang et al.,
2008). A plausible hypothesis of these observations is that, in
physiological conditions, the activation of the PI3K/AKT signalling
pathway contributes to the maintenance of the integrity of EPCs,
leading them to repair the injury. Then, when ROS  increases in
response to stress, the senescence of EPCs may  rise.
p16INK4a and p19ARF are two proteins with anti-proliferative
activity and are transcribed from two different loci on chromosome
9 in humans. p16INK4a is a cyclin-dependent kinase (CDK) inhibitor
that promotes cellular senescence in response to multiple stress-
ors, including oncogene activation, telomere erosion and reactive
oxygen species (Ito et al., 2006; Carlos et al., 2013). p16INK4a
binds cyclin-dependent kinase 4/6 (CDK4/6) and inhibits its activ-
ity, which prevents the phosphorylation of retinoblastoma protein
(Rb) and stops the cell cycle in S/G1 phase. On the other hand,
p19ARF stabilizes the onco-suppressor protein p53 by attenuating
the activity of Mdm-2. In human tumours, p16INK4a is expressed
at high levels and escape from these protective mechanisms is one
of the strategies adopted by the tumour for its survival (Romagosa
et al., 2011). In EPCs prolonged inﬂammatory stimulation by TNF-
increases both the expression of p16INK4a and cellular senescence
independently of changes in telomere length. The overexpression
of p16INK4a is induced via the p38 MAPK pathway, one of the
downstream effectors of ras signalling (Zhang et al., 2009).
External and internal stimuli may  also cause alterations in the
epigenetic maintenance mechanisms of both EPCs and tumour
cells. For example, the concentration of glucose is generally lower
in tumours than in normal tissues. A “glycolytic switch” in cancer
cells occurs: even in the presence of oxygen, cancer cells pre-
fer anaerobic glycolysis rather than oxidative phosphorylation via
the tricarboxylic acid (TCA) cycle for energy production (War-
burg effect) (Cairns et al., 2011; Hirayama et al., 2009). Increased
glycolysis produces higher ATP and NADPH levels, making the
environment more acidic and contributing to the up-regulation of
oxidative stress. Sirtuin-1 (SIRT1) is a protein deacetylase active
upon calorie restriction (Cohen et al., 2004). In response to DNA
damage or oxidative stress SIRT1 has a repressive effect on tumour
suppressor p53 and other transcription factors (Luo et al., 2001;
Motta et al., 2004) thus preventing premature senescence. It has
been demonstrated that either down-regulation of SIRT1 expres-
sion or re-expression of its direct binding partner, caveolin-1,
restores ROS-induced acetylation of p53 and premature senescence
(Volonte et al., 2014). A reduced number of EPCs has been observed
in patients affected by diabetes, where the level of glucose is high
(Rosso et al., 2006). A downregulation of SIRT1, due to the high
level of glucose, correlates with the activation of the transcriptional
activity of the Forkhead transcription factor Fox01 and leads to a
reduced level of EPCs in patients affected by diabetes (Balestrieri
et al., 2008). Notably, SIRT1 is also upregulated by ROS  alone (Wang
et al., 2015). Fox01 is a transcriptional factor that negatively con-
trols cell cycle progression and induces apoptosis in response to
stress (Huang et al., 2006; Chen et al., 2009; Brunet et al., 1999).
When the glucose level is low, as in cancer, the activation of SIRT1
correlates with the decrease of Fox01 levels. Fox01 activity is also
impaired by the over-activation of the PI3K/AKT signalling path-
way. When stress occurs, the pathological inactivation of Fox01
represents a cell survival signal. Moreover, in response to ROS,
EPCs secrete paracrine factors that protect the mature endothelial
cells from stress-induced apoptosis, supporting angiogenesis (Yang
et al., 2010).
Senescence in EPCs is regulated also by a class of small non-
coding RNAs called microRNAs (miRNA or miR). miR  expression can
vary according to internal and external stimuli and their deregu-
lation is associated with a variety of diseases (Manca et al., 2011;
Garbett et al., 2015; Leung and Sharp, 2010; Roufayel et al., 2014;
Taki et al., 2014). It has been shown that the down-regulation of
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iR22, miR10 and miR21 in aged EPCs suppresses senescence and
romotes proliferation (Zhu et al., 2013; Zheng and Xu, 2014). The
p-regulation of miR10b and miR196b in EPCs induced by VEGF and
he release of microvesicles containing the pro-angiogenic miR126
nd miR296 from EPCs correlate with the increase of tumour vas-
ulature (Plummer et al., 2013; Cantaluppi et al., 2012).
The therapies administered to patients affected by cancer repre-
ent another stimulus that may  have effects both on cancer cells and
PCs. Chemotherapeutic regimens involve the administration of
enotoxic compounds that induce cancer cell death. However, this
ype of therapy kills most of the cells in a tissue but is not tumour-
ell speciﬁc. Some cancer cells may  survive and divide again to
evelop a new tumour state. In fact not all patients with the same
reatment have similar outcomes, some may  be therapy-resistant
nd relapse. The reasons for different responses to the same therapy
an be understandable if we consider cancers as a heterogeneous
roup of diseases. One of the most ambitious aims of “person-
lised medicine” is to ﬁnd new patient-speciﬁc therapies. In any
ase, drugs represent an external stimulus that may  have different
ffects on the fate of both cancer cells and EPCs. It has been demon-
trated that certain drugs can rapidly induce EPC mobilisation and
umour homing whereas others do not (Shaked et al., 2008). Fur-
hermore it has been suggested that EPC release after treatment is
art of a host response mediated by the up-regulation of various
ytokines involved in progenitor cell recruitment, such as SDF-1
Roodhart et al., 2010; Sakamori et al., 2012). Platelets activated
y cytokines are one of the main sources of SDF-1.  In particu-
ar, they contain VEGF, TSP-1 and SDF-1, therefore blocking their
ggregation by targeting Platelet-Derived-Growth Factor (PDGF)
ay  results in a reduction of the number of EPCs at the tumour
ite and, consequently, a reduction of the formation of new vessels.
his could in part explain why the addition of anti-angiogenic ther-
ig. 2. Effects of stress on EPCs. EPCs are able to respond to external and internal stresses 
re  able to prevent the proliferation of potential abnormal cells arresting their growth (s
enescence, promoting their survival or undergoing to necrosis depending on crosstalk of
xplode  and release pro-inﬂammatory factors that support the tumour microenvironmengy/Hematology 100 (2016) 177–189
apies enhances the anti-tumour effect of chemotherapy. However,
the effect of other therapies is to induce EPC mobilisation which
contributes to tumour recovery, especially when administered near
the maximum tolerated dose (MTD) (Shaked et al., 2008; Raﬁi et al.,
2008) (Fig. 2).
5. Therapeutic strategies by targeting tumour-associated
EPCs
EPC mobilisation may  contribute to tumour angiogenesis and
formation of metastasis. It has been demonstrated that blocking
EPC mobilisation inhibits vasculogenesis and impairs the formation
of macro-metastasis in vivo (Moccia et al., 2015; Lyden et al., 2001b;
Gao et al., 2008b). Blocking genes involved in the homing of EPCs to
tumour vasculature may  carry the potential for improving antian-
giogenic and antitumor effects. Another anti-tumour strategy could
be to arrest the mobilisation of EPCs from the bone marrow by
inhibiting some of the factors involved in their recruitment. The
main regulator of EPC mobilisation is the chemokine SDF-1. The
disruption of SDF-1 receptor CXCR4 is essential for the egress
of progenitor cells from the bone marrow into the circulation.
Four major classes of CXCR4 antagonists and agonists have been
described: small peptide antagonists and agonists, non-peptide
CXCR4 antagonists, antibodies to CXCR4, and modiﬁed antagonists
and agonists for SDF-1 (Burger and Peled, 2009; Liles et al., 2003;
Abraham et al., 2007). The effect of all these compounds is to pre-
vent the gradient of chemokines that allows the homing of EPCs to
the tumour site.VEGF is another factor involved in EPC mobilisation. Most anti-
angiogenic therapies are based on inhibiting the binding of VEGF
to VEGFR using neutralising antibodies against the ligand or the
receptor, soluble receptors, small molecule inhibitors or therapies
modifying their genetic and epigenetic regulation. In physiological conditions EPCS
enescence). During the tumour progression, EPCs acquire the ability to escape the
 a variety of factors released from the tumour microenvironment. Necrotic EPC cells
t.
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irected against the tyrosine kinase activity of VEGF receptors. It
as been shown that several VEGF-targeted drugs, administered
ither as single agents or in combination with chemotherapy, have
eneﬁcial effects on tumour patients (Miller et al., 2007; Russo
t al., 2015; Barr et al., 2015; Heng et al., 2009). Pre-clinical stud-
es have demonstrated that the disruption of the VEGF signalling
athway negatively modulates EPC-supported vasculogenesis (Qi
t al., 2013; Kerbel and Folkman, 2002). However, some clinical
vidence has revealed that EPCs are also implicated in confer-
ing resistance against vascular disrupting agents. Inhibiting EPC
obilisation using a VEGF-R2 targeting anti-angiogenic drug, or in
d1/Id3 KO transgenic mice, enhances the anti-tumour activity of
he vascular disrupting agent, suggesting that EPCs mediate resis-
ance to the treatment. For this reason it was proposed that EPCs
ay  have a possible role in determining the optimal biological dose
f anti-angiogenic drugs (Shaked et al., 2006; Bertolini et al., 2006;
errara, 2004; Taylor et al., 2012). However the reasons why  EPCs
cquire resistant properties contributing to tumour spread are still
nknown.
Transplantation of genetically modiﬁed bone marrow progeni-
ors may  represent a vehicle for the transport of cytotoxic genes,
ven if the successful translation of gene therapy strategies to
umour treatment is limited due to vector toxicity, poor transduc-
ion efﬁciency and lack of speciﬁcity. Another approach is to block
he genes involved in the homing of EPCs to tumour vasculature
n order to improve anti-angiogenic and anti-tumour effects. In
ny case EPCs can be genetically engineered ex vivo by transduc-
ion with retrovirus and lentivirus vectors, which allow long-term
ransgene expression (Ferrari et al., 2003; Debatin et al., 2008;
evremovic et al., 2004). The primary advantage of using tumour-
argeting EPCs is stable expression of gene targets. Moreover EPCs
an be easily expanded and manipulated without showing prob-
ems of immunological intolerance. However, other issues are
ssociated with their possible use as an anti-tumour tool. First, only
 small number of EPCs are able to be incorporated into tumour
essels. Secondly, the transient resistance of therapeutic EPCs to
heir cytotoxic effectors results in a strong bystander effect on
urrounding tumour cells. Finally, the choice of the most effec-
ive cytotoxic effector to be delivered by the EPCs is difﬁcult to
etermine because of the limited studies available (Debatin et al.,
008).
It has been demonstrated that the delivery of therapeutic agents
o tumour cells enhances the drug concentration in cancer tissues,
mproving their anti-tumour efﬁcacy (Brigger et al., 2002; Ruoslahti
t al., 2010; Büll et al., 2015). The concept of targeted drug deliv-
ry is attractive because it allows for both high local concentration
f the drug and low systemic exposure in patients. In particular,
anoparticles were used as a drug vehicle to target tumour tissues
r cells, protecting the drug from premature inactivation during its
ransport. In vitro and in vivo experiments were performed to tar-
et EPCs for therapeutic cardiac regeneration (Cheng et al., 2014b;
yrtatos et al., 2009). Nanoparticles have been used as a carrier to
arget stem cells, including bone marrow–derived endothelial pre-
ursors, at a speciﬁc location in vivo (Kim et al., 2009; van Noort
t al., 2009). The availability of speciﬁc tumour vascular markers
pens a new avenue for delivering therapeutic agents, genes or pro-
rug enzymes with nanodevices which may  reduce pathological
ngiogenesis (Anderson et al., 2005; Mulder et al., 2005).
Another strategy that can be used to inhibit EPC recruitment
s to reduce the pro-angiogenic factors released in the microen-
ironment mainly by macrophages. Transplantation of genetically
odiﬁed bone marrow progenitors with lentiviral vectors express-ng genes from transcription-regulatory elements of the Tie2/Tek
ene signiﬁcantly reduces the formation of new vessels in tumour
ites (De Palma et al., 2003). The Tie2/Tek gene is preferentially
xpressed in endothelial cells and encodes an angiopoietin recep-gy/Hematology 100 (2016) 177–189 185
tor tyrosine kinase. The same vector was used also to deliver
interferon alpha (INF-) to tumours and resulted in reduction of
new-vessel formation (De Palma et al., 2008). INF- is a cytokine
that shows clinical beneﬁt in the treatment of certain types of
cancer. However, because a high dose is required to obtain a
good response, this regimen has been phased out due to its high
toxicity. The tumour-targeted INF- delivered by Tie2-expressing
monocytes is directly recruited into the tumour site and reduces
angiogenesis through down-regulating the expression of proan-
giogenic factors in tumours. This new anti-cancer therapy may
allow for reduction of EPC recruitment without any substantial
cytotoxic effects because of its speciﬁcity and low-dose require-
ment.
6. Summary and future work
Bone marrow-derived EPCs may  play an important role for
tumour progression due to their ability to form new vessels and
secrete paracrine factors that direct tumour cells to distant sites.
The speculation that EPCs play a crucial role in cancer onset and
progression has been conﬁrmed by clinical studies that show
the high correlation of this cell population with relapse, disease
progression, metastasis and treatment response in human malig-
nancies such as breast, ovarian and non-small-cell lung carcinomas.
However, more studies are necessary to improve our knowledge
about the signalling pathways involved in tumour angiogenesis
associated-metastasis. Elucidating the exact cellular and molecu-
lar mechanisms of tumour angiogenesis modulated by the EPCs is
crucial not only for determining the role of EPCs in pathological
angiogenesis itself but also for better understanding the dynam-
ics that regulate tumour spread. The increased number of bone
marrow-derived EPCs is a common feature in various malignancies;
hence this minor subpopulation of the mononuclear cell fraction
in peripheral blood may  represent the common thread between
different malignancies, representing a good starting point for the
investigation of novel pathways involved in cancer. However, the
involvement of epigenetics in all physiological and pathological
processes makes this scenario more complicated. In fact, the role of
epigenetics has not been completely elucidated and has attracted
increasing interest. Perhaps the main challenge in cancer research is
to understand the contribution and the link between environment
(especially the chronic inﬂammation state), genetics and epigenet-
ics. In this sense EPCs may  represent a turning point.
Some groups are focusing on new strategies to reduce EPC
number, and consequently tumour progression, by delivering ther-
apeutic compounds using nanoparticles. These studies are at the
pre-clinical stage thus are too early to be translated into clinical
practice.
The increase of EPCs in peripheral blood of cancer patients, and
their variation in response to therapies, suggests a possible role
as biomarkers to predict the state of certain cancers but also to
determine the optimal biological dose of anti-angiogenic drugs
considering that EPCs are able to mediate resistance to some anti-
cancer treatments. However, the standard enumeration procedures
or speciﬁc parameters of EPCs have not yet been fully established,
thus more evidence is needed to verify these observations.
In summary, EPCs seem to represent a novel point for the study
of tumour angiogenesis. However, the discovery and characteriza-
tion of EPCs is very recent, with epigenetics being highly involved in
the alteration of EPCs. It is an undeniable fact that further studies are
necessary to understand what genetic and epigenetic changes occur
in EPCs in response to tumour microenvironment and whether it is
possible to translate the emerging discoveries into clinical practice
by optimising the isolation and analysis of EPCs.
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